Is there a biosimilar for tremfya?

Short answer: As of my last update (mid-2024), there were no FDA-approved biosimilars for Tremfya (guselkumab). Several companies have been developing guselkumab biosimilars, but none had completed regulatory approval in the US (and regulatory status can vary by country).

Notes:
- Tremfya is a monoclonal antibody that targets IL-23, used for plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
- A biosimilar is not an exact generic, but a highly similar version with no clinically meaningful differences in safety, purity, or potency. Substitution and interchangeability rules vary by country.

If you’d like, tell me your country or region and I can look up the most current status and any approved or forthcoming guselkumab biosimilars there. Also, if you’re considering cost or treatment changes, discuss with your prescriber about available options and patient assistance programs.